National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Encorafenib (Braftovi®) in combination with cetuximab. HTA ID: 20037

Encorafenib is indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, who have received prior systemic therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 05/08/2020
Rapid review completed 28/09/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of encorafenib plus cetuximab compared with the current standard of care.